Primecap Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $65.9M | Buy |
524,040
+141,600
| +37% | +$17.8M | 0.05% | 176 |
|
|
2025
Q1 | $42.3M | Sell |
382,440
-11,270
| -3% | -$1.25M | 0.04% | 194 |
|
|
2024
Q4 | $53.7M | Sell |
393,710
-10,290
| -3% | -$1.4M | 0.04% | 180 |
|
|
2024
Q3 | $46.5M | Sell |
404,000
-5,290
| -1% | -$610K | 0.03% | 193 |
|
|
2024
Q2 | $56.3M | Buy |
409,290
+9,910
| +2% | +$1.36M | 0.04% | 181 |
|
|
2024
Q1 | $55.1M | Buy |
399,380
+1,057
| +0.3% | +$146K | 0.04% | 183 |
|
|
2023
Q4 | $52.5M | Buy |
398,323
+6,738
| +2% | +$888K | 0.04% | 183 |
|
|
2023
Q3 | $44.1M | Sell |
391,585
-1,775
| -0.5% | -$200K | 0.04% | 187 |
|
|
2023
Q2 | $37.1M | Buy |
393,360
+21,620
| +6% | +$2.04M | 0.03% | 197 |
|
|
2023
Q1 | $37.6M | Buy |
371,740
+366,640
| +7,189% | +$37.1M | 0.03% | 190 |
|
|
2022
Q4 | $609K | Buy |
+5,100
| New | +$609K | ﹤0.01% | 324 |
|